In recent years, the field of hematologic malignancies has witnessed numerous groundbreaking advancements, with Chinese researchers making increasingly significant contributions, particularly in the area of cellular therapy. Their work has greatly accelerated both academic development and clinical practice in this domain. As we step into the new year, Hematology Frontier has invited Dr. Wenbin Qian from The Second Affiliated Hospital of Zhejiang University School of Medicine to provide an in-depth review of CAR-T cell therapy for B-cell lymphoma, summarizing approved CAR-T products, clinical trial data, real-world outcomes, and ongoing challenges. Additionally, this discussion explores strategies for enhancing CAR-T therapy, including novel targets, dual-target CAR-T designs, and gene-editing improvements, aiming to offer valuable insights for clinical practice and future research directions.

Thalassemia, an inherited blood disorder, imposes a significant economic and resource burden on patients, families, and society at large. In recent years, advances in medical research have led to a growing range of treatment options for thalassemia, including traditional blood transfusions and iron chelation therapy, drugs to induce gamma-globin production, hematopoietic stem cell transplantation (HSCT), and emerging approaches like gene and cell therapies, as well as nanomedicine. Among these, gene therapy has garnered particular attention as a potential cure, offering renewed hope to patients worldwide.

Significant progress has been made in the treatment of T-cell lymphomas in recent years. However, challenges persist in managing relapsed/refractory disease, selecting optimal therapies, and determining the best treatment sequencing for patients. To address these issues, the 2024 American Society of Hematology (ASH) Annual Meeting featured an educational session titled Addressing Unmet Needs in T-Cell Lymphomas. This session brought together leading experts to provide insights and practical guidance based on the latest research and clinical experiences. Hematology Frontier had the privilege of speaking with session chair Dr. Neha Mehta-Shah from Washington University’s Siteman Cancer Center. In this discussion, she shared her perspectives on unmet needs, treatment strategies for relapsed/refractory peripheral T-cell lymphoma (PTCL), innovative therapies, and the role of autologous and allogeneic transplants in PTCL.